{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:25:57Z","timestamp":1761017157666,"version":"3.41.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jdcjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jdiacomp.2016.09.005","type":"journal-article","created":{"date-parts":[[2016,9,18]],"date-time":"2016-09-18T21:02:00Z","timestamp":1474232520000},"page":"1-3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial"],"prefix":"10.1016","volume":"31","author":[{"given":"Niki","family":"Katsiki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitri P","family":"Mikhailidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0005","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.3748\/wjg.v21.i22.6820","article-title":"Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update","volume":"21","author":"Athyros","year":"2015","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0010","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.metabol.2016.04.004","article-title":"Pharmacological management of nonalcoholic fatty liver disease","volume":"65","author":"Barb","year":"2016","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.jdiacomp.2016.09.005_bb0015","first-page":"297","article-title":"Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives","volume":"4","author":"Chiarelli","year":"2008","journal-title":"Vascular Health and Risk Management"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0020","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1161\/CIRCULATIONAHA.107.746610","article-title":"Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus","volume":"117","author":"Davidson","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0025","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0030","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with Type 2 diabetes: a randomized trial of pioglitazone. The PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events)","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0035","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00125-016-3902-y","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"59","author":"European Association for the Study of the Liver (EASL)","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0040","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/pds.1722","article-title":"Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis","volume":"18","author":"Habib","year":"2009","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"5","key":"10.1016\/j.jdiacomp.2016.09.005_bb0045","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrendo.2011.233","article-title":"Bone, sweet bone-osteoporotic fractures in diabetes mellitus","volume":"8","author":"Hamann","year":"2012","journal-title":"Nature Reviews. Endocrinology"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0050","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/11587580-000000000-00000","article-title":"Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials","volume":"11","author":"Hernandez","year":"2011","journal-title":"American Journal of Cardiovascular Drugs"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0055","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","article-title":"Non-alcoholic fatty liver disease and dyslipidemia: An update","volume":"65","author":"Katsiki","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0060","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1161\/01.STR.0000071108.00234.0E","article-title":"Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke","volume":"34","author":"Kernan","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0065","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after Ischemic Stroke or Transient Ischemic Attack","volume":"374","author":"Kernan","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0070","doi-asserted-by":"crossref","first-page":"e4455","DOI":"10.1097\/MD.0000000000004455","article-title":"Long-term effects of pioglitazone on first attack of ischemic cerebrovascular disease in older people with type 2 diabetes: A case-control study in Taiwan","volume":"95","author":"Lai","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0075","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2015.7996","article-title":"Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes","volume":"314","author":"Lewis","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0080","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials","volume":"298","author":"Lincoff","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0085","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/j.1463-1326.2008.00892.x","article-title":"Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials","volume":"10","author":"Mannucci","year":"2008","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0090","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/MJT.0b013e318167180c","article-title":"Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials","volume":"15","author":"Nagajothi","year":"2008","journal-title":"American Journal of Therapeutics"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0095","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","article-title":"Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0100","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3797\/scipharm.1407-16","article-title":"Pioglitazone and Endothelial Dysfunction: Pleiotropic Effects and Possible Therapeutic Implications","volume":"82","author":"Radenkovic","year":"2014","journal-title":"Scientia Pharmaceutica"},{"issue":"7","key":"10.1016\/j.jdiacomp.2016.09.005_bb0105","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1592\/phco.30.7.716","article-title":"Bone loss and fracture risk associated with thiazolidinedione therapy","volume":"30","author":"Riche","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14740330802597821","article-title":"How safe is the use of thiazolidinediones in clinical practice?","volume":"8","author":"Rizos","year":"2009","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0115","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.atherosclerosis.2010.12.021","article-title":"Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects","volume":"215","author":"Rizza","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0120","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1161\/ATVBAHA.112.300346","article-title":"Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors","volume":"33","author":"Saremi","year":"2013","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"2","key":"10.1016\/j.jdiacomp.2016.09.005_bb0125","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2174\/1874467211205020248","article-title":"Effects of PPAR? agonists against vascular and renal dysfunction","volume":"5","author":"Sugawara","year":"2012","journal-title":"Current Molecular Pharmacology"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0130","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.5551\/jat.30007","article-title":"Effects of Pioglitazone for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed Diabetes: The J-SPIRIT Study","volume":"22","author":"Tanaka","year":"2015","journal-title":"Journal of Atherosclerosis and Thrombosis"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0135","doi-asserted-by":"crossref","first-page":"734","DOI":"10.2337\/dc06-1539","article-title":"Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease","volume":"30","author":"Tolman","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0140","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/bcp.12306","article-title":"Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis","volume":"78","author":"Turner","year":"2014","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0145","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.numecd.2012.09.003","article-title":"Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial","volume":"22","author":"Vaccaro","year":"2012","journal-title":"Nutrition, Metabolism, and Cardiovascular Diseases"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0150","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/01.STR.0000257974.06317.49","article-title":"Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)","volume":"38","author":"Wilcox","year":"2007","journal-title":"Stroke"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0155","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.diabres.2015.06.005","article-title":"Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease (JDDM 36)","volume":"109","author":"Yokoyama","year":"2015","journal-title":"Diabetes Research and Clinical Practice"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0160","first-page":"563","article-title":"Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study","volume":"21","author":"Yoshii","year":"2014","journal-title":"Journal of Atherosclerosis and Thrombosis"},{"key":"10.1016\/j.jdiacomp.2016.09.005_bb0165","first-page":"429","article-title":"Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk","volume":"9","author":"Zou","year":"2013","journal-title":"Vascular Health and Risk Management"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872716304184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872716304184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T19:47:42Z","timestamp":1749584862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872716304184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1056872716304184"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.09.005","relation":{},"ISSN":["1056-8727"],"issn-type":[{"type":"print","value":"1056-8727"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}